OCUMENSION THERAPEUTICS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.47 HKD | +7.83% |
|
+8.92% | -3.14% |
| Apr. 15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
| Apr. 15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
Evolution of the average Target Price on Ocumension Therapeutics
Price target over the last 5 years
History of analyst recommendation changes
79537a391367f612b11e69d.tnKWIErbb4hAe77QpKAd2vIX5M8Uo1TWKrmQxXaSX0c.mzbiax6yDvoUC_Kg7eZYvZxViIpR6wGiXe29kgeiMy2GR8ETE4kI4wkt2Q~a602ca60d5bb7b92c3e70b9bf955b0f7
Analysts' Consensus
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
5.989
CNY
Average target price
7.77
CNY
Spread / Average Target
+29.74%
High Price Target
11.32
CNY
Spread / Highest target
+89.06%
Low Price Target
5.518
CNY
Spread / Lowest Target
-7.87%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Ocumension Therapeutics
| UBS |
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
- Stock Market
- Equities
- 1477 Stock
- Consensus Ocumension Therapeutics
